Compare GPRO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPRO | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 169.4M |
| IPO Year | 2014 | 2021 |
| Metric | GPRO | SGMT |
|---|---|---|
| Price | $0.76 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | ★ 4.3M | 334.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $651,542,000.00 | $2,000,000.00 |
| Revenue This Year | $23.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $1.73 |
| 52 Week High | $3.05 | $11.41 |
| Indicator | GPRO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 52.43 |
| Support Level | $0.69 | $4.97 |
| Resistance Level | $1.02 | $6.72 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 88.96 | 91.11 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.